MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
曼恩凯德生物医疗的Afrezza在曼恩凯德生物医疗的第4阶段试验中展示了对糖尿病患者的A1c控制能力
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups – one that utilized Afrezza (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery...
曼恩凯德生物医疗公司（NASDAQ:MNKD）是一家专注于开发和商业化吸入治疗产品和设备，用于治疗内分泌和孤儿肺部疾病患者的公司。其今日宣布了第4阶段INHALE-3研究30周的高级结果，该研究显示在...
登录免费看全文
登录/注册
资讯热榜
更新时间